Table 2 ELABELA levels according to demographic findings in patients with CLL
From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Group | Variables | ELABELA (ng/ml) | p |
|---|---|---|---|
CLL | Gender | ||
Female | 8.6 (0.6–19.7) | 0.062 | |
Male | 6.3 (0.6–11) | ||
Age | r = 0.056 | 0.728 | |
Control | Gender | ||
Female | 3.5 (0.2–8.6) | 0.234 | |
Male | 1.3 (0.1–7.0) | ||
Age | r = −0.003 | 0.985 | |